Floatz logo

PIBRENTASVIR

Hepatitis C Virus Infection

AbbVieSmall moleculePhase 3Dormant
A
84/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
78/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Hepatitis C Virus Infection cohort.

Asset / SponsorPhaseRating
Veruprevir
AbbVie
Phase 4A
Daclatasvir
MTI University
Phase 4A
Velpatasvir
Peking University People's Hospital
Phase 4A
GLECAPREVIR
AbbVie
Phase 3A
OMBITASVIR
AbbVie
Phase 3A

View all 50 →

Same molecule, other indications

PIBRENTASVIR is also rated in:

chronic hepatitis C virus infectionDormant
A
Indicative · Phase 3
80 / 100
View asset →
cirrhosis of liverDormant
BBB
Indicative · Phase 3
72 / 100
View asset →
HIV infectious diseaseDormant
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →